Bayer, Onyx seek liver-cancer approval for Nexavar
Bayer AG and Onyx Pharmaceuticals Inc. said on Wednesday that it asked U.S. regulators to approve their Nexavar drug as a treatment for liver cancer.
Nexavar, which is already approved for kidney cancer, earlier this month showed in a study that it could extend the life of patients with advanced liver cancer, adding about three months of survival compared with a placebo.
(Reporting by Lewis Krauskopf)
© Copyright Thomson Reuters 2024. All rights reserved.
Join the Discussion
Editor's pick